拉米夫定治疗时发生HBV P基因区耐药变异的相关预测因素研究(3)
 |
| 第1页 |
参见附件(1626KB，2页)。
[6] 刘艳,胡毅,乐晓华,等.拉米夫定治疗慢性乙型肝炎1～3年随访结果[J].中华传染病杂志,2004,6(3):204～206.
[7] Chien RN, Liaw YF, Atkino M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B.Asia Hepatitis Laminvdine Trial Group[J]. Hepatology,1999,30(3):770～774.
[8] Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop:Roadmap for management ofpatients receiving oral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol,2007,5(8): 890～897.
[9] Bauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine[J].J Infect Dis,1999,180(6):1757～1762.
[10] Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy[J]. Hepatology, 2001,34(4 Pt 1):785～791.
[11] Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir[J]. Eur J Gastroenterol Hepatol, 2002, 14(9): 1007-1011.
[12] Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics in chronic hepatitis B patients during lamivudine therapy[J].Liver,2002,22(2):121～126.
您现在查看是摘要介绍页，详见PDF附件(1626KB，2页)。